MAP2K7 and neoplasm: Interestingly, one phase I trial for the novel Mitogen-activated protein kinase kinase (MEK) inhibitor RO5126766 reported a tumor patient with HRAS mutation that showed 20% tumor shrinkage due to MEK inhibitor treatment [7].